Samson Clinical ( Samson ), an Australian pharmaceutical company focused on developing innovative treatments for hair loss, today announced the successful completion of recruitment ...

Fondazione Telethon announces the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

Black box warnings are the highest level of caution that the FDA requires for certain potentially dangerous products. Makary, at a press conference Monday, cited several studies touting the benefits ...

Amid high demand for mental health care, some individuals have turned to AI chatbots for emotional support — but a new study ...

Study researchers noted that the findings suggest the association between anxiety and improved OS was at least partly related to the higher incidence of irAEs, which implies that, in people with an ...

On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology ...

Before voters go to the ballot box, they’re sitting on their therapist’s couch—where they’re unpacking their Mamdani-induced ...

NEW ORLEANS – A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that ...

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

Researchers sought to determine whether glofitamab would induce responses in real-world cases of relapsed or refractory DLBCL.

Eruptive xanthoma is considered a rare disease with an incidence of 18 out of 100,000. It can only be seen in 10% of patients ...